{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:34:42Z","timestamp":1789756482729,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018955","name":"NIHR Leeds Musculoskeletal Biomedical Research Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ard.2025.01.006","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:34:57Z","timestamp":1738827297000},"page":"435-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics"],"prefix":"10.1016","volume":"84","author":[{"given":"Paolo","family":"Gisondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Galeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Turati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Idolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.01.006_bib0001","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ard.2025.01.006_bib0002","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","article-title":"Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis","volume":"8","author":"Zabotti","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.ard.2025.01.006_bib0003","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.01.006_bib0004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.01.006_bib0005","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.01.006_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.662047","article-title":"The molecular pathophysiology of psoriatic arthritis-the complex interplay between genetic predisposition, epigenetics factors, and the microbiome","volume":"8","author":"Carvalho","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"11","key":"10.1016\/j.ard.2025.01.006_bib0008","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.006_bib0009","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","article-title":"Does biologic therapy impact the development of PsA among patients with psoriasis?","volume":"81","author":"Meer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.01.006_bib0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.01.006_bib0011","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"issue":"10136","key":"10.1016\/j.ard.2025.01.006_bib0012","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ard.2025.01.006_bib0013","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.006_bib0014","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.006_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.01.006_bib0016","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.01.006_bib0017","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2025.01.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003143","article-title":"Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce","volume":"9","author":"De Marco","year":"2023","journal-title":"RMD Open"},{"issue":"19","key":"10.1016\/j.ard.2025.01.006_bib0019","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.ard.2025.01.006_bib0020","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jaad.2024.06.106","article-title":"Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: a population-based analysis","volume":"91","author":"Strober","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.ard.2025.01.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.006_bib0022","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","article-title":"Enthesitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2025.01.006_bib0023","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ard.2025.01.006_bib0024","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaad.2020.08.060","article-title":"Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational studies","volume":"84","author":"Xie","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ard.2025.01.006_bib0026","doi-asserted-by":"crossref","first-page":"257","DOI":"10.55563\/clinexprheumatol\/8thj0l","article-title":"Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence","volume":"38","author":"Solmaz","year":"2020","journal-title":"Clin Exp Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:33:18Z","timestamp":1762086798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0003496725000512"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.006","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}